DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors (NCT01375842).
https://clinicaltrials.gov/ct2/show/NCT01375842?term=NCT01375842&rank=1 (Stand: 06.02.2018)
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.